Intellia Therapeutics - investor relations

Skip to main navigation

Contact
Info
CRISPR/Cas9
Programs
Investors & Media
Careers

stock information

Copyright West LLC. Minimum 15 minutes delayed.

press releases

–

Mar 31, 2020

Summary Toggle FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

events and presentation

There are currently no events to display.

corporate governance

corporate governance

financial information

financial information

stock<br />
information

stock
information

investor<br />
FAQs

investor
FAQs

information<br />
request

information
request

IR<br />
contacts

IR & Media
contacts

analyst coverage

Info

Overview
Leadership
Partners

Careers

Our DNA
Why We’re Here
Job Openings
Benefits

CRISPR/Cas9

What’s CRISPR/Cas9?
How CRISPR/Cas9 Works
Types of Edits

Programs

Our Full-Spectrum Approach
Pipeline
In Vivo Therapies
Ex Vivo Therapies

Investors & Media

Press Releases
Scientific Publications and Presentations
Corporate Deck
Events & Presentations
Press Kit

© Intellia Therapeutics 2020

terms of use
privacy policy

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.